15 December 2004
Screening for Pregnancy Endpoints
Two University of Auckland medical researchers are leading a major international study aimed at predicting and
eventually preventing the three major diseases of late pregnancy.
The SCOPE (Screening for Pregnancy Endpoints) study begins this month in Auckland, where the researchers will be
recruiting 3000 women who are pregnant for the first time with a single child. This initiates the international study in
which 15,000 women are expected to participate.
Associate Professors Lesley McCowan and Robyn North from the Faculty of Medical and Health Sciences say the overall goal
of SCOPE is to produce a clinically useful screening test for three late pregnancy conditions: preeclampsia (a severe
high blood pressure complication triggered by pregnancy); fetal growth restriction; and spontaneous preterm birth.
"These conditions complicate almost one in five first pregnancies, and cause significant maternal and infant ill-health
or death worldwide. In more than half the affected pregnancies, the conditions are so severe the mother and/or the baby
require admission to an intensive care unit, or result in death of the fetus or newborn baby," say Associate Professors
McCowan and North.
"In the developed world, an estimated $NZ41 billion is spent annually on healthcare costs to provide antenatal care,
neonatal intensive care and hospitalisation for first time mothers and babies affected with these diseases.
"All three conditions can have lifelong consequences for the child. These range from severe disabilities including
significant neuro-developmental delay, deafness and blindness, to milder learning and behavioural disabilities.
"Although there are known therapies that could prevent approximately one third of cases if high risk women could be
identified, there are no effective methods of screening for these diseases early in the first pregnancy."
The SCOPE study will establish a high-quality biobank that can then be used as a platform for scientific discovery and
the development of predictive tests. Initial methods of prediction developed will be based on clinical and lifestyle
information. The biobank will also provide the necessary blood and urine specimens for identification of novel
combinations of molecular "markers" that could indicate if a woman was at high risk of one or more of the three late
pregnancy conditions being studied by the SCOPE team.
The researchers will then evaluate the predictive potential of these markers - and hope to develop a method of offering
first time mothers an accurate risk rating for each of the three important pregnancy complications.
"Reliable risk prediction will enable preventative treatment for first time mothers at high risk. It will also mean less
intervention for women at low risk," say Associate Professors McCowan and North.
The SCOPE research collaborators are: Auckland University of Technology; University of London (UK); University of Leeds
(UK); University of Manchester (UK); Adelaide University (Australia); University of California, San Francisco (USA);
University of Texas, Galveston (USA); Karolinska Institute (Sweden); Technical University of Munich (Germany).
The SCOPE team has received major funding from the Foundation of Research, Science and Technology and the Health
Research Council of New Zealand.
Any women in Auckland interested in participating in the study can contact the researchers on: 09 308 2300.
ENDS